IDH1 and glioma: The matrisome heterogeneity across tumor niches was further characterized using single cell transcriptomics data from 201,986 glioma, immune, and other stromal cells in 16 IDH WT GBM and 2 IDH mutant low-grade glioma tumors from patients {Abdelfattah, 2022 #100}.